Compare HOVR & XTNT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HOVR | XTNT |
|---|---|---|
| Founded | 2013 | N/A |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Blank Checks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 103.1M | 82.6M |
| IPO Year | N/A | N/A |
| Metric | HOVR | XTNT |
|---|---|---|
| Price | $1.71 | $0.83 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | ★ $6.50 | $1.50 |
| AVG Volume (30 Days) | ★ 652.6K | 231.4K |
| Earning Date | 01-13-2026 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.01 |
| Revenue | N/A | ★ $133,083,000.00 |
| Revenue This Year | N/A | $15.95 |
| Revenue Next Year | $55.08 | N/A |
| P/E Ratio | ★ N/A | $68.87 |
| Revenue Growth | N/A | ★ 16.88 |
| 52 Week Low | $0.35 | $0.34 |
| 52 Week High | $4.18 | $0.95 |
| Indicator | HOVR | XTNT |
|---|---|---|
| Relative Strength Index (RSI) | 46.78 | 63.71 |
| Support Level | $1.57 | $0.70 |
| Resistance Level | $1.79 | $0.81 |
| Average True Range (ATR) | 0.14 | 0.06 |
| MACD | 0.02 | 0.02 |
| Stochastic Oscillator | 39.53 | 81.42 |
New Horizon Aircraft Ltd is an aerospace Original Equipment Manufacturer that is designing and building a next-generation hybrid electric vertical take-off and landing aircraft for the regional air mobility market. Its aircraft will offer a more efficient way to move people and goods at a regional scale, help to connect remote communities, and advance its ability to deal with an increasing number of climate-related natural disasters such as wildfires, floods, and droughts. The company aims to deliver a hybrid electric 7-seat aircraft, called the Cavorite X7, that can take off and land vertically like and helicopter.
Xtant Medical Holdings Inc is a medical technology company focused on the design, development, and commercialization of a comprehensive portfolio of orthobiologics and spinal implant systems to facilitate spinal fusion in complex spine, deformity and degenerative procedures. Its products are used by orthopedic spine surgeons and neurosurgeons to treat a variety of spinal disorders in the cervical, thoracolumbar, and interbody spine. The company's biomaterial products include OsteoSponge, OsteoSponge SC, OsteoSelect Plus DBM putty, OsteoWrap, and the line of 3Demin products, as well as other allografts. It generates a majority of its revenue from the U.S.